D2l Pharma Research Solutions Private Limited, a active private limited company, was established on 06 July 2007 in Hyderabad, Telangana, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U24232TG2007PTC054728. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹5.00 M and a paid-up capital of ₹2.88 M.
It upholds a compliant status. Employing 47 professional, Its leadership includes Marella Ravikant (Whole-Time Director), Shekhar Gupta (Whole-Time Director), Kode Sashi Kiran (Managing Director). Past directors included Marella Ravikant, Ratna Kumari Kode, Shekhar Gupta. It holds ₹2.60 Cr open charges and ₹2.60 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at H.No: 16-11-16/75, Plot No.75 Sripuram Colony, Malakpet, Hyderabad, Telangana, 500036.
U24232TG2007PTC054728
054728
06 July 2007
₹5.00 M
₹2.88 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into D2l Pharma Research Solutions Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Marella Ravikant | Whole-Time Director | 05 Feb 2010 | Current |
| Shekhar Gupta | Whole-Time Director | 18 Jan 2008 | Current |
| Kode Sashi Kiran | Managing Director | 06 Jul 2007 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 02 Apr 2012 | Past |
| Pramod Abcsdd | Director | 10 Oct 2012 | Past |
| Pramod Abcsdd | Director | 02 Apr 2012 | Past |
| Pramod Abcsdd | Director | 02 Apr 2012 | Past |
| Pramod Abcsdd | Director | 07 Jul 2007 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
D2L Pharma Research Solutions Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.08% decrease. The company also saw a substantial fall in profitability, with a 36.54% decrease in profit. The company's net worth moved up by a moderate rise of 4.74%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, D2L Pharma Research Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹26,000,000.00
₹26,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Apr 2020 | Others | ₹2.60 Cr | Satisfied |
Explore comprehensive loan charge details -
D2L Pharma Research Solutions has a workforce of 47 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of D2L Pharma Research Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D2L Pharma Research Solutions's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge registered on 30 Apr 2020 via Charge ID 100337127 with Others was fully satisfied on 03 Jun 2025. was documented.
The activity D2L Pharma Research Solutions Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
The activity D2L Pharma Research Solutions Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was completed.
The activity A charge with Others of Rs. 26.00 M registered on 30 Apr 2020 with Charge ID 100337127 was modified on 30 Oct 2023. was completed.
Progress on A charge with Others amounted to Rs. 26.00 M with Charge ID 100337127 was registered on 30 Apr 2020. was documented.
Progress on Marella Ravikant was appointed as a Whole-time director was appointed as a Whole-time director on 05 Feb 2010 & has been associated with this company since 15 years 9 months . was documented.
The CIN of D2l Pharma Research Solutions Private Limited is U24232TG2007PTC054728.
D2l Pharma Research Solutions Private Limited is headquartered at H.No: 16-11-16/75, Plot No.75 Sripuram Colony, Malakpet, Hyderabad, Telangana, 500036.
D2l Pharma Research Solutions Private Limited was incorporated on 06 July 2007.
The current directors of D2l Pharma Research Solutions Private Limited are
The primary industry of D2l Pharma Research Solutions Private Limited is Professional, Scientific And Technical.
D2l Pharma Research Solutions Private Limited is unlisted.
The authorized capital of D2l Pharma Research Solutions Private Limited is ₹5.00 M, and the paid-up capital is ₹2.88 M.
The compliance status of D2l Pharma Research Solutions Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX